IR Release

This document has been prepared in accordance with accounting principles and practices generally accepted in Japan, and translated for reference only from the original Japanese version. The Company gives no warranty with respect to its correctness.

The original disclosure in Japanese was released on Oct. 21, 2021

Takara Holdings Inc.

Revision of Consolidated Business Results Forecast for the First Half of the Fiscal Year Ending March 31, 2022

Kyoto, Japan—Takara Holdings announced revisions to the business results forecast for the first half of the fiscal year ending March 31, 2022 (from April 1, 2021, to March 31, 2022) that it released on August 3, 2021, as stated below. These revisions were based on consideration of recent performance trends.
 

1. Revised figures for the business results forecast for the first half of the fiscal year ending March 31, 2022 (from April 1, 2021, to September 30, 2021)

2. Reason for revision
For the first half of the fiscal year ending March 31, 2022, overall consolidated net sales are expected to exceed the previous forecast (announced on August 3, 2021) with higher net sales for the Takara Bio Group, although net sales for Takara Shuzo are projected to be lower than the forecast.
　　In terms of profit, operating income, ordinary income, and net income attributable to owners of the parent are expected to exceed the previous forecast, with higher gross profit due to the increase in net sales and a decrease in the cost of sales ratio.
For the six months ended September 30, 2021, net sales and all profit items are projected to be at all-time highs.
The performance by each business segment is as follows.

[Takara Shuzo]
In Japan, the market for products for commercial use has slumped as a result of the prolonged state of emergency due to COVID-19, and products such as sake and shochu in particular have faced harsh conditions. In addition, with regard to light-alcohol refreshers, the impact of the voluntary product recall implemented in the first quarter has extended through the second quarter, and overall net sales for the first half of the fiscal year ending March 31, 2022 are expected to be lower than the previous forecast.
　　Operating income is expected to exceed the previous forecast, as a result of efforts to generate profits through thorough cost reduction.

[Takara Shuzo International Group]
In overseas markets, net sales for the first half of the fiscal year ending March 31, 2022 are expected to slightly exceed the previous forecast, due to a strong performance in exports from Japan, in addition to a recovery in the eating and drinking establishment market and the expansion of sales channels to retailers and online sales, among others.
　　Operating income is expected to exceed the previous forecast, as a result of holding down SG&A expenses, in addition to an increase in net sales.

[Takara Bio Group]
In the Biomedical Business, net sales are expected to exceed the previous forecast for general research reagents, which are continuing to recover from the impact of COVID-19, and PCR testing-related products for COVID-19.
　　Operating income is expected to exceed the previous forecast, with an anticipated increase in the profit margin due to factors such as an increase in net sales and an improvement in the cost of sales ratio for contract services.
　

　Further, today consolidated subsidiary Takara Bio Inc. (The First Section of Tokyo Stock Exchange, security code number: 4974) also announced revisions to forecasts for the six-month period ended September 30, 2021

3. Full-year business results forecast for the fiscal year ending March 31, 2022
The Company is currently evaluating whether or not revisions to forecasts for consolidated business results for the full fiscal year are necessary and considering the details of possible revisions. The Company will make an announcement in this regard when it announces its business results for the first half on November 9, 2021.
 

*The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the business result figures scheduled to be announced on November 9, 2021.